The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2013Validation of Blood-borne Autoantibody Biomarkers for Parkinson’s Disease Supplement
Promising Outcomes of Original Grant:
The purpose of the original study was to determine if a small group of selected blood-borne autoantibody biomarkers that were previously shown to be effective in... -
Research Grant, 2013Six-month Oral Toxicity Study of the Accordion Pill™ of Carbidopa/Levodopa
Objective/Rationale:
The Accordion Pill™ is designated to significantly stabilize the pharmacokinetic profile of drugs with a narrow absorption window, such as levodopa. Regular controlled-release... -
Rapid Response Innovation Awards, 2013Transcranial Direct Current Stimulation for the Treatment of Parkinson’s Disease
Objective/Rationale:
Current treatments for Parkinson’s disease (PD) are either associated with side effects, expensive, or their efficacy diminishes over time. Thus, the development of practical... -
MJFF Research Grant, 2013A New Tool for CSF-Based Parkinson Disease Diagnostics: Super-Resolution Microscopy Investigation of Alpha-Synuclein Aggregates
Objective/Rationale:
It is still difficult to diagnose Parkinson’s Disease (PD) patients through routine assays. Clinical research on PD suggests that the aggregation (clumping) of the... -
Target Validation, 2013Validation of the Transcriptional Repressor Bach1 as a Novel Target to Enhance Antioxidant Response Pathway and Block Neurodegeneration in Parkinson’s Disease
Objective/Rationale:
Bach1 is a transcriptional repressor, which is a protein that binds to a specific DNA site and prevents transcription of nearby genes. Bach1 is primarily localized to... -
RRIA (Rapid Response Innovation Awards), 2013Proof-of-concept Study for the Development of Non-invasive Immunotherapy for Parkinson’s Disease: Intranasal Targeting of Immunoglobulin G Antibodies and Fragments to the CNS
Objective/Rationale:
Immunotherapy using antibodies directed against alpha-synuclein is an extraordinarily promising, potentially disease-modifying treatment approach for Parkinson’s...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.